fingolimod hydrochloride has been researched along with Hepato-Pulmonary Syndrome in 1 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 1 (100.00) | 2.80 |
Authors | Studies |
---|---|
Baweja, S; Bihari, C; Kumar, G; Kumar, J; Kumari, A; Maiwall, R; Mourya, AK; Negi, P; Rastogi, A; Reddy, GS; Sarin, SK; Sarohi, V; Sood, AK; Subudhi, PD; Thangariyal, S; Tomar, A; Tripathi, DM; Vashistha, C | 1 |
1 other study(ies) available for fingolimod hydrochloride and Hepato-Pulmonary Syndrome
Article | Year |
---|---|
Hepatopulmonary syndrome is associated with low sphingosine-1-phosphate levels and can be ameliorated by the functional agonist fingolimod.
Topics: Animals; Fingolimod Hydrochloride; Hepatopulmonary Syndrome; Inflammation; Liver Cirrhosis; Mice; Niacinamide; Rats; Rats, Sprague-Dawley | 2023 |